Key Takeaways
CG Oncology (NASDAQ: CGON) confirmed its timeline to complete a rolling Biologics License Application for its lead oncolytic immunotherapy, cretostimogene, by the fourth quarter of 2026, positioning the company to tap a bladder cancer market segment with no currently approved therapies. The company also expects top-line data from a separate Phase 3 trial in a larger patient population in the first half of the year.
"We believe everything is going on track and according to plan," CEO Arthur Kuan said at a recent investor conference, citing recent discussions with the U.S. Food and Drug Administration that provided "alignment and clarity" for the submission in high-risk non-muscle invasive bladder cancer (NMIBC).
The initial BLA targets the BCG-unresponsive high-risk NMIBC population, a market of roughly 25,000 patients. A second BLA is planned for 2027 for intermediate-risk NMIBC, which Kuan described as a market of about 50,000 patients. The company is also exploring cretostimogene in combination with other drugs, including gemcitabine. Prior studies of cretostimogene monotherapy have shown a 42% complete response rate at two years.
For investors, the confirmation of the regulatory timeline and manufacturing readiness are key steps. With an annual manufacturing capacity of 50,000 vials and a stated goal to increase that tenfold, CG Oncology is building the infrastructure to compete with potential rivals like Johnson & Johnson's TAR-200 and AstraZeneca's Imfinzi. The company's focus on an intravesical, in-clinic administration could offer a practical advantage over more complex procedures.
CG Oncology is preparing for a potential commercial launch by building out its medical and health system teams. President and Chief Operating Officer Ambaw Bellete highlighted the therapy's administrative advantages, contrasting the 20-minute intravesical delivery of cretostimogene with the cystoscopic procedures required for competing products like TAR-200.
The company believes durability of response will be a key differentiator. Management noted that a durability label extending beyond the 12 months seen in a competing product would represent significant upside. On pricing, executives stated that cretostimogene would be priced on a per-dose basis, with the high-risk indication requiring about 30 doses over three years, while the intermediate-risk regimen involves 14 doses in the first year.
Top-line data from the Phase 3 PIVOT-006 trial in intermediate-risk NMIBC is anticipated in the first half of 2026. Kuan said that based on physician feedback, a 30% relative risk reduction is the minimum clinically meaningful bar for the trial to be considered a success, setting a clear benchmark for the upcoming data release.
This article is for informational purposes only and does not constitute investment advice.
